Introduction
Rheumatoid arthritis (RA) is an autoimmune disease with a prevalence of 0.5-1.0% in adults (1) . RA causes swelling and pain of the joints (mainly the hands, wrists, and feet), reducing functional ability. This can substantially impact both physical and mental quality of life (QoL) (2) . Mental health disorders are highly prevalent; 17% of RA patients have depressive disorder according to diagnostic interview (3), and 25.1% of rheumatology outpatients screen positive for anxiety disorder (4) . These estimates are substantially higher than those in the general population, in which estimates of the prevalence of depression are typically~5% (5) . Poor mental health is associated with numerous deleterious outcomes in RA, including increased risk of mortality (6) , work disability (7), worsened disease activity and physical function (8-10), higher pain (11) , and fatigue (12) .
There is increasing evidence suggesting common inflammatory pathways in RA and depression. Specifically, the levels of inflammatory cytokines, including tumor necrosis factor (TNF) and interleukin-6 (IL-6), can be elevated in individuals with depressive disorder (13) , and recent evidence suggests that therapies used in RA to target TNF inhibitors may improve mental health outcomes in depressed patients with high levels of inflammation (14) and those with chronic physical illness (15) .
RA management has evolved in the last 25 years, with earlier diagnosis and earlier, more aggressive treatment (16) . The "treat-to-target" framework emphasizes the desired goal of reaching a state of remission by switching medications until this target has been achieved (17, 18) . Initial treatment typically involves conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), usually methotrexate (MTX). In the UK, treatment with more expensive targeted biologic DMARDs is reserved for patients with an insufficient response to 2 csDMARDs (19) . For the purposes of this review, we use the term biologic DMARDs to encompass both targeted biologic and JAK treatments. Although there has been evident improvement in radiographic outcomes and inflammation, the impact on physical function and QoL is less pronounced (20, 21) . The limited impact of treatment on QoL is of concern, given that psychosocial well-being and social function are of key importance to patients (15) .
Because low mood is highly prevalent in RA (3), and psychosocial well-being is important to patients (22) , it might be expected that mental health is commonly assessed as an outcome in RA clinical trials. However, a 2009 systematic review found that mental health outcomes were reported in 4% of RA clinical studies (23) , increasing to 22% with a broader conceptualization of mood including mental health components of QoL, using questionnaires such as the Medical Outcomes Study Short Form 36 (SF-36) survey (24) .
The aim of this study was to systematically review evidence regarding the efficacy of pharmacotherapy for improving mental health outcomes in RA. The objectives were to identify the frequency with which mental health outcomes are measured and reported in RA pharmacotherapy trials; to quantify the impact of biologic DMARDs on mental health outcomes, in comparison with self-reported physical health outcomes; and to investigate factors that may influence RA pharmacologic treatment efficacy for mental health outcomes, such as treatment mode of action, patient demographics, and clinical characteristics.
Identification of trials
A protocol and data extraction form was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (25) statement (see Appendix 1, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40565/abstract). We searched the Cochrane Central Register of Controlled Trials, PsycINFO, Medline, Embase, Web of Science, and CINAHL from inception to March 2017. Search terms are available in Study Protocol (Appendix 2, available at http://onlinelibrary.wiley.com/ doi/10.1002/art.40565/abstract). We also screened reference lists of reviews and ClinicalTrials.gov registry for trials that are still in progress. Titles were first screened for relevance, followed by abstracts and full texts to assess eligibility for inclusion. Author FM screened 100% of the articles, and author ER followed the same procedure for 10% (460 of 4,604) of the identified articles.
Selection criteria
Types of patients, study design, and treatment types. Studies providing data for adult RA patients aged >18 years were included. Studies spanning several disease groups were eligible only if the results for RA patients were reported separately. Randomized controlled trials of biologic DMARD pharmacologic treatments for managing RA, including drugs in use in clinical practice at the time of the study and new drugs under investigation, were eligible. Generic pain relief medication or alternative and complementary therapies such as acupuncture or collagen were excluded. Trials including active comparators (biologic DMARD versus biologic DMARD), placebo control groups (biologic DMARD versus placebo), or usual care control groups (biologic DMARD versus csDMARD) were included, as were trials with multiple arms (biologic DMARD versus biologic DMARD versus csDMARD). For crossover trials, data were extracted for the first period only, to avoid potential carryover effects. Pragmatic trials, with patients shifting between treatment modalities and dosages according to treatment response, were included in a narrative synthesis.
Outcomes. Our primary outcome of interest was mental health, as assessed by both traditional depression and anxiety questionnaires and generic measures of QoL that include mental health subscales. Data derived from these questionnaires were included if they were reported from mental health subscales separately from overall QoL or disability scores.
Based on previous systematic review evidence (23) , we anticipated that the SF-36 would be the most commonly used questionnaire. If the reported data were derived from >1 mental health questionnaire, data derived from the SF-36 were prioritized for inclusion in metaanalysis to reduce heterogeneity and aid interpretation. The SF-36 has 8 domains assessing various aspects of mental and physical well-being, as follows: physical function (PF), role physical (RP), global health (GH), bodily pain (BP), vitality (V), social function (SF), role emotional (RE), and mental health (26) . These domains can be combined to form 2 higher-order summary scores: physical component summary (PCS) and mental component summary (MCS). The PCS is formed by positively weighting the physical domains (PF, RP, GH, and BP) and negatively weighting the mental domains (V, SF, RE, and mental health), and the MCS is calculated by positively weighting the mental domains and negatively weighting the physical domains. The PCS and MCS summary scores are interrelated (27) yet provide an indicator of the impact of treatment on physical outcomes in comparison with mental outcomes, with higher scores indicating improved mental/ physical QoL. PCS scores were considered secondary outcome data, to allow comparison between mental QoL and physical QoL outcomes following RA treatment.
Data extraction
Data were extracted from all eligible studies (n = 71) by 2 reviewers (FM and ER) independently, to minimize human error in reporting results (see Appendix 3, available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40565/abstract). In the case of incomplete reporting of data, we searched the ClinicalTrials.gov registry, accessed company-specific registries, contacted authors directly, and made data requests to funding bodies as necessary.
Risk of bias
A key assessment of the quality of the information provided by a trial is the potential for bias in the treatment effect estimate. The risk of bias of included trials was assessed by 2 reviewers (FM and ER), using the Cochrane Collaboration tool (28) . This assessed random sequence generation; allocation concealment; participant, personnel, and outcome assessor blinding; completeness of outcome data; and selective reporting. When necessary, these data were obtained from "parent" primary outcome papers, in which more detailed methodologic information is included.
The quality of each outcome was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. A rating of high, moderate, low, or very low was given to each outcome (MCS and PCS), based on assessment of risk of bias, inconsistency (between estimated effect sizes across studies and estimated I 2 heterogeneity), indirectness (applicability of study to the review aim), imprecision, and risk of publication bias (Appendix 4, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40565/abstract).
Statistical methods
Standardized mean difference (SMD) effect sizes were calculated for each comparison, using group means and SDs. The SMD indicates the size of the treatment effect relative to the observed variability in the outcome and can be interpreted as the between-group difference in SD units, where an SMD of 0.5 indicates an SD difference of one-half. A rule of thumb is that SMDs of 0.2, 0.5, and 0.8 are interpreted as small, medium, and large effects, respectively (29) . When multiple doses of the same drug were tested, the most commonly used dosage, or the dosage most reflective of that used in clinical practice, was included in the pooled meta-analysis. Whereas dose-finding studies of new drugs used a range of doses, in the meta-analysis, the mean score across dosages was used. End point means were prioritized; however, mean change scores were included when end point scores were unavailable. If no mean scores or SDs were available after accessing the ClinicalTrials.gov registry or contacting authors and funding sources, effect sizes were calculated using any available statistical estimates, including T scores, 95% confidence intervals (95% CIs), and P values (30) . Missing SD data were imputed by calculating the mean SD from data available from other studies using the same outcome, drug, and dosage at the same time point.
The analysis involved a random-effects pairwise meta-analysis (PMA), due to expected heterogeneity, including all studies regardless of comparator, using Stata version 14. Subgroup analyses compared active treatment separately with no treatment (placebo) and with csDMARD controls. Statistical heterogeneity in the between-study treatment effects was assessed using I 2 values, with scores of 25%, 50%, and 75% representing low, moderate, and high heterogeneity, respectively (31) . The pooled treatment effect estimated may not be trustworthy when heterogeneity is high. Additionally, meta-regression analysis was used to investigate between-study differences in design and patient characteristics that might account for variability in between-study treatment effects. Study sample size, age, proportion female, disease duration, baseline mood, baseline disease activity, follow-up time in weeks, rheumatoid factor (RF) status, recruitment year, and availability of data were entered individually in studies of biologic DMARDs versus csDMARDs. A significant difference between analyses was established when CIs did not overlap.
Studies examining biologic DMARDs versus csDMARDs were used in network meta-analysis (NMA) of targeted therapies according to mode of action. NMA is an extension of traditional PMA to multiple treatment comparisons, which allows indirect comparisons to be made between different types of treatment (32) . For example, if both etanercept and abatacept have been compared directly with MTX in different trials, the relative effectiveness of etanercept versus abatacept can be estimated indirectly. This method also has the benefit of combining direct and indirect comparisons to provide a more precise (i.e., smaller standard errors) estimate of the effect size (32) .
Because the NMA grouped treatment according to mode of action, it was necessary to exclude studies comparing biologic DMARDs with the same mode of action without a csDMARD or placebo control arm. Typically, such studies concerned a biologic DMARD biosimilar. Effect sizes were presented as pooled SMDs and 95% CIs. Direct and indirect estimates of effect size were compared for biologic DMARD subcategories when direct comparisons were available, and comparison-adjusted funnel plots were created to indicate differences in effect sizes between small and large studies. Targeted treatments were ranked based on the estimated probability of each targeted treatment being most effective for MCS and PCS outcomes, calculated using surface under the cumulative ranking curve (SUCRA). SUCRAs combine the estimated probabilities (derived from the NMA) that each treatment is the first best, second best, and so on for all possible ranks (see Appendix 4, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40565/abstract). Higher SUCRA values indicate a greater likelihood of a given treatment being the most efficacious, such that when the SUCRA value is 1, the treatment is certain to be the best, and when it is 0, it is certain to be the worst.
Search results and included participants
A total of 71 studies, involving 34,796 participants, were identified ( Figure 1 and Table 1 ). Full references for these studies are provided in Appendix 5 (available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40565/abstract). The mean age of the patients ranged from 47 years to 57.5 years, 78.6% were female, and the mean disease duration ranged between 0.1 years and 12.3 years. The mean baseline MCS score was 42.2, and the mean baseline Disease Activity Score in 28 joints (DAS28) (33) was 6.2. The studies considered 16 biologic DMARDs: anti-TNFs (adalimumab, certolizumab, etanercept, golimumab, and infliximab), B cell inhibitors (rituximab, SBI-087), T cell inhibitors (abatacept), anti-IL-6 (clazakizumab, sarilumab, sirukumab, tocilizumab), and JAK inhibitors (baricitinib, decernotinib, fostamitinib, and tofacitinib).
Objectives
Objective 1: Frequency of mental health outcome measurement. Of the 71 eligible studies in which evidence of mood had been measured in either an abstract, methods, or as a list of outcomes in the ClinicalTrials.gov registry, only 36 (50.7%) provided mental health data in either publications, supplementary material, or open online data summary reports. Attempts were made to contact authors and funding sources for 32 of the remaining 35 studies for which insufficient information was available (3 did not have contact information or funding information available); only 12 (36.4%) of these contact attempts resulted in receipt of the necessary data. Of the remaining 23 studies for which no data were available, imputation of the missing information (e.g., SD of the outcome) was possible for 12 studies (allowing inclusion in the meta-analysis), 4 showed some data that were added to the narrative synthesis (Appendix 6 available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.40565/abstract), and 7 could not be included in any outcome assessment. A total of 57 studies were included in the PMA, and 54 were included in the NMA. The 3 studies omitted from the NMA were head-to-head trials of targeted therapies with the same mode of action.
Objective 2: Impact of RA treatment on mental health. Results of the PMA and subgroup analyses to examine the impact of RA treatment on mental health outcomes are shown in Table 2 . The total analysis involving 57 studies, with no exclusions and all comparators, revealed a statistically significant but modest effect of all treatments on mental health-related QoL (MCS) (SMD 0.21). This indicates that, on average, biologic DMARDs were associated with a treatment effect, compared with control treatments, of approximately one-fifth of an SD, which is equivalent to añ 2-point difference in MCS units. In comparison, the impact of RA treatments on physical health-related QoL (PCS) was somewhat greater (SMD 0.41) and equivalent to a difference of~4 points on the PCS scale. I 2 values reflected moderate-to-high levels of heterogeneity for both the PCS (I 2 = 76.5) and the MCS (I 2 = 59.2) outcomes. This suggests that estimates may not be a robust indicator of effect, potentially due to moderating factors such as differences in trial design.
When the analysis was limited to no-treatment placebo controls, biologic DMARDs had a substantial benefit for PCS but not MCS outcomes (SMD 0.52 and SMD 0.27, respectively). Comparisons with csDMARD controls did not significantly alter the findings from the total analysis (SMD 0.47 and 0.24, respectively). For both analyses, heterogeneity levels were reduced compared with the any-comparator analysis but remained moderate (>40%) for both MCS and PCS outcomes. Subgroup analysis of unpublished data provided by authors and funding sources revealed little difference in the impact of biologic DMARDs on MCS and PCS in comparison with background-csDMARD control groups, when compared with all trials.
A csDMARD (typically MTX) was a common comparator against which all biologic DMARDs had been assessed (see Appendix 7, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40565/abstract). NMA results for biologic DMARDs versus csDMARDs are shown in Figure 2 . These results demonstrated consistently small effect sizes for the MCS outcome and a moderate effect size for the PCS outcome. All biologic DMARDs performed better than csDMARDs for improving MCS and PCS outcomes, although there were no notable differences in outcomes between different biologic DMARD modes of action. Effect sizes for MCS outcomes were typically 50% smaller than PCS effect sizes. Figure 3 shows the comparatoradjusted funnel plot for the NMA MCS outcome analysis, demonstrating no substantial publication bias. SUCRA rankings (Figure 2) showed that for MCS outcomes, among the drugs considered in the analysis, biologics targeting anti-IL-6 had a 90% probability of being the most effective treatment for improving MCS outcomes; abatacept had an 83% probability of most effectively improving PCS outcomes.
Objective 3: Variables associated with the impact of RA treatment on mood outcomes. The results of the meta-regression analyses, which included studies of background csDMARD comparators, are shown in Table 3 . These results showed that sample size, age, proportion female, baseline MCS, disease activity, RF status, year of recruitment, and availability of baseline data were not associated with variability in the treatment effect sizes in the PMA results for MCS or PCS outcomes. There was a small but significant positive association between disease duration and MCS outcomes and number of follow-up weeks and PCS outcomes. This indicated that every increased year of disease duration was associated with a 0.04 increase in the MCS effect size (i.e., a reduction in treatment efficacy), and every increased week of followup time was associated with an increase of 0.01 in the PCS effect size.
Risk of bias assessment
The GRADE assessment suggested that the MCS and PCS outcome PMA of biologic DMARDs versus csDMARDs was of moderate quality. Although there was no serious indirectness, imprecision, or publication bias, few studies were completely without risk of bias, and there was moderate heterogeneity. A full summary of the risk of bias assessment is provided in Appendix 4 (available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40565/abstract).
Summary
Despite mental health problems being highly prevalent (3), predictive of worse disease outcomes and treatment response (8, 34) , and being highlighted as a priority for outcome measurement by patients (35, 36) , 74 (51.0%) of 145 otherwise eligible trials did not measure mental health and were excluded from this systematic review. Of the 71 eligible studies indicating that mental health had been measured, 35 (49.3%) did not provide estimates of treatment effects. The results of PMA of 57 trials of targeted treatment showed a relatively small but significant impact of biologic DMARDs on mental health as assessed by the SF-36. The impact of targeted RA treatment on SF-36 MCS was approximately half the effect seen on the SF-36 PCS. The largest effect size for MCS outcomes was 0.30, as observed for the anti-IL-6 versus csDMARD comparison; the lowest effect size was 0.19, as observed for kinase inhibitors.
To date, TNF has been the primary focus of research investigating the inflammatory mechanisms involved in the presence of depressive symptomatology. Infliximab was recently investigated as an antidepressant in patients with treatment-resistant depression (14) , and the impact of anti-TNF medications on depression outcomes in patients with chronic physical illness was addressed in a recent systematic review and meta-analysis of 6 trials (15). Building on this review (15), we focused only on RA but included broader conceptualizations of mental health and more treatment types. By including treatments with varied modes of action, we hoped to pinpoint the mechanism through which RA treatment may have benefits for mental health. However, we failed to find any major variations between treatment modes of action. Although we observed one of the largest effects on mental health for treatments targeting IL-6, the smallest effect size was observed for anti-TNF treatments. Therefore, it remains largely unclear as to the extent to which improvements in mental health are through biologic DMARDs directly impacting inflammatory pathways or simply indirectly through a reduction in pain and disability.
Meta-regression analysis identified a small but significant association between disease duration and MCS effect size, and the largest (although not significant) R 2 value for comparing data that had been published online versus unpublished data that was requested from authors. Although we found no clear evidence of publication bias in our funnel plots, there may be a tendency for nonsignificant mental health outcomes to be omitted in published studies (37) .
For this review, we used reproducible and rigorous methods to collate and synthesize the data in this field. We included many trials, representing >20,000 patients, and the study quality was relatively high. There are some restrictions that limit the interpretation of our results. We used broad inclusion criteria for the entry of studies into this review, preferring to use subgroup analyses and metaregression analysis to examine sources of statistical heterogeneity in the PMA, which was substantial. In addition to heterogeneity due to the different types of biologic DMARDs included, heterogeneity may also be explained by the comparator used, plus variability in disease duration and length of follow-up between studies. Another source of heterogeneity may be that we did not restrict our focus to trials specifically recruiting patients with low mood at baseline. The overall mean MCS score at baseline was 42.2, with 20.8% of studies showing a mean MCS score below a threshold of 40, indicated as a threshold for possible mood disorder (38) . Most patients included in the studies may not have had mood disorder at baseline, which restricts the potential to identify an "antidepressant" effect.
NMA methodologies are being more widely used in medical research; however, there are limitations to this technique that need to be addressed. First, it is important to highlight that, because treatment allocations have been randomized within (not between) trials, NMA can provide only observational evidence (39) . NMA assumes transitivity (whether any patient could be given any treatment in the network) and consistency (similar estimates obtained from direct and indirect comparisons). Our focus on biologic DMARDS, which are relatively recently developed, typically involve similar inclusion criteria and generally are considered to be equally efficacious (40) , limits the potential for violation of the transitivity assumption. Regarding the consistency assumption, examining loop-specific heterogeneity, we observed no specific cause for concern.
Despite not limiting our search strategy to the SF-36, we identified the SF-36 as the most commonly used tool for measuring mental health, and data from the SF-36 were prioritized to allow meaningful comparisons across studies. Although this measure allows for an interesting comparison between mental and physical QoL outcomes, it is important to acknowledge that the SF-36 MCS captures a broader conceptualization of mental health-related QoL. It includes symptoms of depression and anxiety, but also vitality/fatigue, and impacts social and emotional functioning (24) . Future research may benefit from identifying subgroups of patients who may be susceptible to experiencing mental health benefits following RA treatments and understanding how these patients may differ from those who are more resistant to improvement. This may provide useful clinical information for anticipating the treatment response, because improvement in mental health in turn is likely to further impact physical symptoms (34) and may also identify potentially useful intervention targets. A focus on RA patients with symptoms indicating mental health problems at baseline may provide insight into any benefits of RA treatment in a subgroup of patients with both increased inflammation and a psychological disorder.
Conclusions
Advances in RA treatment have resulted in significant improvements in specific outcomes: the delay of radiographic damage and reduction of inflammation and adverse events (41) . However, this review demonstrates that relying on RA pharmacotherapy alone may not meaningfully improve mental health outcomes. Mental health is treatable in patients with physical illness (42, 43) , and the measurement and management of mental health throughout the course of treatment as part of routine practice is recommended (44) . Our results suggest that mental health in patients with RA must be addressed, and that mental health problems are unlikely to resolve with effective pharmacologic management of RA alone. Providing integrated, dedicated mental health care within routine practice is essential to achieve parity of esteem, valuing mental and physical health equally.
